Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
mTOR–neuropeptide Y signaling sensitizes nociceptors to drive neuropathic pain
Lunhao Chen, … , Yue Wang, Zhihua Gao
Lunhao Chen, … , Yue Wang, Zhihua Gao
Published October 4, 2022
Citation Information: JCI Insight. 2022;7(22):e159247. https://doi.org/10.1172/jci.insight.159247.
View: Text | PDF
Research Article Neuroscience

mTOR–neuropeptide Y signaling sensitizes nociceptors to drive neuropathic pain

  • Text
  • PDF
Abstract

Neuropathic pain is a refractory condition that involves de novo protein synthesis in the nociceptive pathway. The mTOR is a master regulator of protein translation; however, mechanisms underlying its role in neuropathic pain remain elusive. Using the spared nerve injury–induced neuropathic pain model, we found that mTOR was preferentially activated in large-diameter dorsal root ganglion (DRG) neurons and spinal microglia. However, selective ablation of mTOR in DRG neurons, rather than microglia, alleviated acute neuropathic pain in mice. We show that injury-induced mTOR activation promoted the transcriptional induction of neuropeptide Y (Npy), likely via signal transducer and activator of transcription 3 phosphorylation. NPY further acted primarily on Y2 receptors (Y2R) to enhance neuronal excitability. Peripheral replenishment of NPY reversed pain alleviation upon mTOR removal, whereas Y2R antagonists prevented pain restoration. Our findings reveal an unexpected link between mTOR and NPY/Y2R in promoting nociceptor sensitization and neuropathic pain.

Authors

Lunhao Chen, Yaling Hu, Siyuan Wang, Kelei Cao, Weihao Mai, Weilin Sha, Huan Ma, Ling-Hui Zeng, Zhen-Zhong Xu, Yong-Jing Gao, Shumin Duan, Yue Wang, Zhihua Gao

×

Figure 2

Rapamycin treatments inhibit mTOR activation and attenuate mechanical allodynia and heat hyperalgesia after SNI.

Options: View larger image (or click on image) Download as PowerPoint
Rapamycin treatments inhibit mTOR activation and attenuate mechanical al...
(A) Experimental schedule for rapamycin or vehicle along with BrdU administration through intraperitoneal (i.p.) injection. (B) Representative blots indicating the decreased p-S6 levels in the ipsilateral DRG and SDH following 7-day continuous i.p. injection of rapamycin or vehicle in Mtorfl/fl mice after SNI. (C) Quantitation of p-S6/S6 in DRGs and SDH following rapamycin treatments (n = 3 mice per group). (D–F) Measurements of mechanical allodynia (n = 12–13 per group) (D), heat hyperalgesia (n =7–8 per group) (E), and cold allodynia (n = 7–8 per group) (F) with daily i.p. injection of rapamycin or vehicle after SNI. (G and H) Representative images of Iba1 and BrdU immunolabeling in superficial SDH (dotted regions) after treated with Veh (G) or rapamycin (H) at day 3 after SNI. Boxes show regions of higher magnification in SDH, while arrowheads indicate Iba1+ BrdU+ mitotic microglia. Scale bars: 100 and 20 μm for low- and high-magnification images, respectively. (I and J) Quantitative analysis of microglia per square millimeter (I) and the percentage of mitotic microglia in total microglia (J) in both contralateral and ipsilateral SDH at day 3 after SNI (n = 5–7 mice per group). Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, using 2-way ANOVA followed by Bonferroni’s post hoc tests among group (D–F), 2-tailed unpaired Student’s t tests (C), or 1-way ANOVA followed by Bonferroni’s post hoc tests (I and J). Rap, rapamycin; Veh, vehicle; BL, baseline; D, day; SDH, spinal dorsal horn; PWT, paw withdraw threshold.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts